This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Consumer Staples, Communication, Consumer DiscretionaryWIA2020 | Next 50 in Global Tech: Consumer Technology
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
Exclusive Interview with Ray Hu, Founder and Managing Partner of Blue Lake Capital
Updated 9 hours ago
An Overview of China’s Robotaxi Industry in 2022 for Overseas Investors
Updated 13 hours ago